Several novel agents such as DOT1L and FLT3 inhibitors that demonstrated selective targeting of KMT2A-r leukemia cells in preclinical models, have unfortunately failed to live up to their expectations in clinical trials (21, 22). Here, DOT1L is linked to leukemia.